The α‐ and β‐adrenoceptor blocking activities of labetalol and its RR‐SR (50:50) stereoisomers
Open Access
- 1 December 1991
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 104 (4) , 823-828
- https://doi.org/10.1111/j.1476-5381.1991.tb12513.x
Abstract
We compared the α1, α2‐ and β1‐adrenoceptor blocking potencies of labetalol with those of its two stereoisomers (RR and SR) in pithed rats and in homogenized rat cerebral cortex and heart. In pithed rats, labetalol and the RR‐SR combination were given orally either at doses of 25 and 50 mg kg−1 body wt. or intravenously at doses of 1 and 5 mg kg−1 body wt. Prazosin 4 and 20 μg kg−1 body wt. and propranolol 1 and 5 mg kg−1 body wt., were given intravenously for comparison studies of potency at α1‐ and β1‐adrenoceptors, respectively. Effects were studied before and after i.v. administration of either phenylephrine (at doses which increased the mean arterial pressure by approximately 80 mmHg) or isoprenaline (at doses that increased heart rate by approximately 100 beats min−1). In pithed rats, labetalol and the RR‐SR combination antagonized, in a dose‐dependent manner, the pressor effect of phenylephrine (P < 0.05) and the chronotropic effect of isoprenaline (P < 0.05). Following both oral and intravenous dosing, the RR‐SR combination was twice potent as labetalol in terms of α1‐and β1‐adrenoceptor antagonism at equivalent doses. Labetalol and the enantiomers lacked affinity at α2‐adrenoceptors while at α1‐adrenoceptors the order of potency was prazosin ≫ RR‐SR > labetalol. At β1‐adrenoceptors, the affinity of the compound RR‐SR was about 3 times that of labetalol. As labetalol is a mixture of active (RR and SR) and inactive (SS and SR) enantiomers (in terms of α‐ and β‐receptor actions), the combination of RR and SR may be a valuable substitute for labetalol in the treatment of systemic hypertension. Although the potential for non‐specific side effects (common to all four enantiomers) could be expected to be diminished, recent reports by postmarketing surveillance indicate that the RR isomer (dilevalol) can induce liver toxicity. Interestingly, labetalol is devoid of this effect; whether the combination of RR and SR enantiomers could be of clinical importance warrants further investigation.Keywords
This publication has 23 references indexed in Scilit:
- DilevalolDrugs, 1990
- Dilevalol compared with propranolol and placebo for systemic hypertensionThe American Journal of Cardiology, 1989
- Influence of beta2 agonism and beta1 and beta2 antagonism on adverse effects and plasma lipoproteins: Results of a multicenter comparison of dilevalol and metoprololThe American Journal of Cardiology, 1989
- Biochemical Characterization of a New Highly Cardioselective β-Adrenoceptor AntagonistJournal of Pharmacy and Pharmacology, 1988
- Importance of Drug Enantiomers in Clinical PharmacologyDrugs, 1985
- NL-FIT: A microcomputer program for non-linear fittingComputer Programs in Biomedicine, 1983
- SPBS: Statistical programs for biological sciences Minicomputer software for applying routine biostatistical methodsComputer Programs in Biomedicine, 1982
- Binding characteristics of 3H-prazosin to rat brain α-adrenergic receptorsEuropean Journal of Pharmacology, 1979
- Alpha-noradrenergic receptor binding in mammalian brain: Differential labeling of agonist and antagonist statesLife Sciences, 1976
- Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reactionBiochemical Pharmacology, 1973